Literature DB >> 14594440

Pharmaceutical expenditure and therapeutic value of new medicines in Spain.

Josep Darba.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14594440     DOI： 10.2165/00019053-200321160-00005

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  2 in total

1.  Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.

Authors:  C Camps-Herrero; L Paz-Ares; M Codes; R López-López; A Antón-Torres; P Gascón-Vilaplana; V Guillem-Porta; A Carrato; J J Cruz-Hernández; C Caballero-Díaz; A Blasco-Cordellat; J A Moreno-Nogueira; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2014-06-13       Impact factor: 3.405

Review 2.  Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.

Authors:  Maria Buti; Miguel A Casado; Leslie Fosbrook; Rafael Esteban
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.